ORCA
Online Research @ Cardiff

Clear Cookie - decide language by browser settings

Bridging the age gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer

Battist, Nicolo Matteo Luca, Reed, Malcolm W. R., Herbert, Esther, Morgan, Jenna L., Collins, Karen A., Ward, Sue E., Holmes, Geoffrey R., Bradburn, Michael, Walters, Stephen J., Burton, Maria, Lifford, Kate

, Edwards, Adrian

, Robinson, Thompson G., Martin, Charlene, Chater, Tim, Pemberton, Kirsty J., Shrestha, Anne, Brennan, Alan, Cheung, Kwok Leung, Todd, Annaliza, Audisio, Riccardo A., Wright, Juliet, Simcock, Richard, Green, Tracey, Revell, Deirdre, Gath, Jacqui, Horgan, Kieran, Holcombe, Chris, Winter, Matthew C., Naik, Jay, Parmeshwar, Rishi, Gosney, Margot A., Hatton, Matthew Q., Thompson, Alastair M., Wyld, Lynda and Ring, Alistair 2021. Bridging the age gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. European Journal Of Cancer 144 , pp. 269-280. 10.1016/j.ejca.2020.11.022

Preview	PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (858kB) \| Preview
Preview	PDF (Supplemental Materials) - Supplemental Material Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (894kB) \| Preview
Preview	PDF (Tables and Figures) - Supplemental Material Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (475kB) \| Preview

Official URL: http://dx.doi.org/10.1016/j.ejca.2020.11.022

Abstract

Introduction Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a key determinant of treatment acceptance. We aimed to investigate its effect on quality of life in older patients enrolled in the Bridging the Age Gap study. Materials and methods A prospective, multicentre, observational study of EBC patients ≥70 years old was conducted in 2013–2018 at 56 UK hospitals. Demographics, patient, tumour characteristics, treatments and adverse events were recorded. Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires (EORTC-QLQ) C30, BR23 and ELD 15 plus the Euroqol-5D (eq-5d) over 24 months and analysed at each time point using baseline adjusted linear regression analysis and propensity score-matching. Results Three thousand and four hundred sixteen patients were enrolled in the study; 1520 patients undergoing surgery and who had high-risk EBC were included in this analysis. 376/1520 (24.7%) received chemotherapy. At 6 months, chemotherapy had a significant negative impact in several EORTC-QLQ-C30 domains, including global health score, physical, role, social functioning, cognition, fatigue, nausea/vomiting, dyspnoea, appetite loss, diarrhoea and constipation. Similar trends were documented on other scales (EORTC-QLQ-BR23, EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18–24 months in unmatched and matched cohorts. Conclusions The negative impact of chemotherapy on quality-of-life is clinically and statistically significant at 6 months but resolves by 18 months, which is crucial to inform decision-making for older patients contemplating chemotherapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	0014-2964
Date of First Compliant Deposit:	13 January 2021
Date of Acceptance:	14 November 2020
Last Modified:	05 Nov 2024 20:15
URI:	https://orca.cardiff.ac.uk/id/eprint/137615